Results 91 to 100 of about 11,390 (207)
Vascular Health and Risk Management, 2011 Takeshi Takami1, Yoshihiko Saito21Department of Internal Medicine, Clinic Jingumae, Kashihara, Japan; 2First Department of Internal Medicine, Nara Medical University, Kashihara, JapanPurpose: The aim of this study was to compare the effects of olmesartan
Takami T, Saito
doaj
Кардиоваскулярная терапия и профилактика, 2011 Background. For patients with hypertension, effective 24-hour blood pressure (BP) control is vital to ensure protection against the early morning surge in BP and the associated increased risk of cardiovascular events.
Hans R. Brunner, Kikuo Arakawa
doaj +1 more source
Angiotensin II-inhibition:effect on Alzheimer's pathology in the aged triple transgenic mouse [PDF]
, 2012 Reducing excessive accumulation of amyloid-β (Aβ) in Alzheimer's disease (AD) is a key objective of most AD therapies, and inhibition of angiotensin-converting enzyme (ACE) may delay onset or progression of AD. The effects of an ACE-inhibitor (ACE-I) and
Ferrington, Linda +5 more
core +6 more sources
Frontiers in Pharmacology, 2019 A new, simple, sensitive, selective, rapid, and high-throughput liquid chromatography-tandem mass spectrometry (LC-MS/MS) method has been developed and validated for simultaneous quantification of Olmesartan and hydrochlorothiazide in human plasma ...
Arvind Kumar +3 more
doaj +1 more source
Drug treatment of hypertension: focus on vascular health [PDF]
, 2016 Hypertension, the most common preventable risk factor for cardiovascular disease and death, is a growing health burden. Serious cardiovascular complications result from target organ damage including cerebrovascular disease, heart failure, ischaemic heart
Cameron, Alan C. +2 more
core +1 more source
Enhancement of Dissolution Rate of Olmesartan Medoxomil Using Urea as Carrier by Different Solid Dispersion Techniques [PDF]
, 2018 The poor solubility of drug substances in water and their low dissolution rate in aqueous G.I.T fluid often leads to insufficient bioavailability. As per Biopharmaceutical Classification System (BCS), Olmesartan belongs to the class-II category having ...
Gomathi, M. (M), Sangameswaran, B. (B)
core
Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension
Vascular Health and Risk Management, 2006 Mark GreathouseSouth Hills Cardiology Associates of Pittsburgh, Pittsburgh, PA, USAAbstract: In most patients with hypertension, especially Stage 2 hypertension, adequate control of blood pressure (BP) is only achieved with combination drug therapy. When
Mark Greathouse
doaj
Enteropathy Associated with Olmesartan
GE: Portuguese Journal of Gastroenterology, 2016 The recognition of an enteropathy caused by olmesartan is recent. It was first described in 2012 by the Mayo Clinic, which presented 22 clinical cases. Olmesartan is a highly prescribed drug and the differential diagnosis of a sprue-like enteropathy is ...
Bruno Moreira da Silva +6 more
doaj +1 more source
P-67: Dose response antihypertensive efficacy of aliskiren (SPP 100), an orally active renin inhibitor [PDF]
, 2017 Aliskiren (SPP 100), an orally active renin inhibitor, has been shown to inhibit the production of angiotensin I and angiotensin II in healthy volunteers.
Barton, John +5 more
core
Olmesartan/amlodipine: a review of its use in the management of hypertension
Vascular Health and Risk Management, 2011 R KreutzInstitute of Clinical Pharmacology and Toxicology, Charité, Universtitätsmedizin – Berlin, GermanyAbstract: Combination therapy is an effective strategy to increase antihypertensive efficacy in those patients with poor blood ...
Kreutz R
doaj